相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumor mutational burden on cytological samples: A pilot study
Francesco Pepe et al.
CANCER CYTOPATHOLOGY (2021)
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Denis L. Jardim et al.
CANCER CELL (2021)
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Kevin Litchfield et al.
CELL (2021)
Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase
Cristina Valero et al.
JAMA ONCOLOGY (2021)
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
D. J. McGrail et al.
ANNALS OF ONCOLOGY (2021)
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
A. Galvano et al.
ESMO OPEN (2021)
Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors
Mohamed E. Salem et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No
V. Prasad et al.
ANNALS OF ONCOLOGY (2020)
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) >= 10: a decision centered on empowering patients and their physicians
V. Subbiah et al.
ANNALS OF ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy
Aparna R. Parikh et al.
ONCOLOGIST (2019)
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
Aaron M. Goodman et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Implementing TMB measurement in clinical practice: considerations on assay requirements
Reinhard Buettner et al.
ESMO OPEN (2019)
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials
Hossein Maymani et al.
LUNG CANCER (2018)
Landscape of Tumor Mutation Load, Mismatch RepairDeficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
Mohamed E. Salem et al.
MOLECULAR CANCER RESEARCH (2018)
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Carl Morrison et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
Roman Groisberg et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Immunotherapy with Single Agent Nivolumab for Advanced Leiomyosarcoma of the Uterus: Results of a Phase 2 Study
Eytan Ben-Ami et al.
CANCER (2017)
Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience
Maria Schwaederle et al.
MOLECULAR CANCER THERAPEUTICS (2016)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
分享论文
